A5050207609- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Heavy Metal Exposure and Toxicity
- Multiple and Secondary Primary Cancers
- Cancer Risks and Factors
- Trace Elements in Health
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Chronic Lymphocytic Leukemia Research
- Virus-based gene therapy research
- Occupational exposure and asthma
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Endometrial and Cervical Cancer Treatments
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Chronic Myeloid Leukemia Treatments
- Potassium and Related Disorders
- Biological Research and Disease Studies
- Breast Implant and Reconstruction
- Diversity and Career in Medicine
Mayo Clinic in Arizona
2017-2025
Mayo Clinic
2018-2024
WinnMed
2018-2022
Wayne State University
2016
University of Toronto
2013-2014
513 Background: Adjuvant endocrine therapy (AET) improves overall survival (OS) in patients (pts) with hormone receptor (HR) positive early-stage breast cancer (BC). For pts estrogen (ER)-low BC (defined as ER 1-10%), there is controversy regarding AET benefit, given tumor heterogeneity (>40% basal; (1)), and similar chemotherapy response prognosis to ER-negative (neg) BC. Current guidelines categorize ER-low a separate entity suggest equipoise benefit. We previously determined that...
Background: Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify maximum tolerated dose (MTD), pharmacokinetics (PK), dosing schedule, and adverse events (AEs) patients with advanced solid tumors. Patients Methods: received oral bimiralisib determine the MTD one continuous (once daily) two intermittent schedules (A: Days 1, 2 weekly; B: 4 weekly) until progression or unacceptable AEs occurred. Results:...
PURPOSE Adjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%) is unclear. METHODS Using National Cancer Database, we studied patients high-risk stage I to III, (defined as immunohistochemistry who received (neo)adjuvant chemotherapy and did or not initiate ET. OS was analyzed initiation a time-dependent covariate using Cox proportional hazards...
529 Background: Neoadjuvant chemotherapy (NAC) is commonly administered to patients (pts) with estrogen receptor alpha (ER) negative (immunohistochemistry [IHC] 0%) and ER-low (IHC 1-10%) breast cancer (BC). For pts without pathological complete response (pCR), ER expression may differ between baseline residual BC following NAC. We previously demonstrated adjuvant endocrine therapy (ET) omission in early-stage was associated significantly worse overall survival (OS); however, this effect...
Abstract The toxic metal ion cadmium (Cd 2+ ) induces pleiotropic effects on cell death and survival, in part through signaling mechanisms cytoskeletal dynamics. Linking these phenomena appears to be calmodulin‐dependent activation of the Ca /calmodulin‐dependent protein kinase II (CaMK‐II). Here we show that interference with dynamics filamentous actin cytoskeleton, either by stabilization or destabilization, results disruption focal adhesions at ends organized structures, particular loss...
11145 Background: T-DXd is increasingly used in mBC. A toxicity of special interest interstitial lung disease/pneumonitis (ILD), occurring 10-15% pts the DESTINY-Breast trials, and with potential lower incidence/severity earlier line settings [Krop et al, ASCO 2023]. However, routine practice, may be more heavily pre-treated mBC previously exposed to other antibody-drug conjugates (ADC) [Premji al SABCS We evaluated related ILD at Mayo Clinic. Methods: retrospectively identified who received...
Abstract Introduction: CDK 4/6 inhibitors (CDK4/6i) are FDA approved for treatment of hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). Recent work demonstrated that a rise in MCV was correlated with longer median progression free survival (Anampa et al, Haemoatologica 2018). We performed single-institution retrospective analysis to evaluate whether palbociclib induced early changes serve as pharmacodynamic biomarker predict response CDK4/6i. Methods: identified...
Abstract Background: Germline Pathogenic Variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are known to increase breast cancer (BCa) risk, but the effect of these PVs on tumor biology is not well-understood. Ki-67 an established prognostic marker hormone receptor (HR) positive distribution associated with germline known. Methods: The study included patients loco-regional (Stage I-III) HR-positive (ER+ or PR+), HER2-negative invasive ductal lobular evaluated at Mayo Clinic for curative...
5562 Background: Platinum-resistant or refractory ovarian cancer remains a hard-to-treat disease given the poor prognosis and survival rates. Immune checkpoint inhibitors (ICI; such as pembrolizumab) have not been approved in this indication. Igrelimogene litadenorepvec (Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123), is an oncolytic adenovirus encoding for IL-2 TNFa, designed to selectively lyse tumor cells while recruiting activating T-cells, turning immunologically cold tumors hot. The...
TPS5630 Background: Platinum-resistant ovarian cancer (PROC) portends a poor prognosis and, although treatments are available, response rates low. Previous studies have demonstrated that DNA topoisomerase I (TOP1) inhibitors exhibit clinical activity in PROC. Irinotecan also has 15-25% rate some of platinum-resistant epithelial but does not FDA approval for this indication. Additional preclinical models suggest TOP1 poisons more active if administered at low doses on prolonged schedules....
A 56-year-old female presented for acute onset headache, cloudy vision, peripheral vision loss, and floaters in the left eye. Eight months prior, she was diagnosed with T-cell lymphoblastic leukemia (ALL) (balanced 6;20 7;16 translocations fluorescence situ hybridization (FISH) positive heterozygous CDK2NA deletion) treated hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating high-dose cytarabine methotrexate a matched, unrelated donor allogeneic blood stem cell...
A critical appraisal and clinical application of Bart BA, Goldsmith SR, Lee KL et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296-2304. doi: 10.1056/NEJMoa1210357
Abstract Background: HER2-positive invasive lobular carcinoma (ILC) of the breast is a rare entity. Treatment decisions for cancer are often extrapolated from ductal subtype but clinical outcomes and prognostic factors not well defined. Methodology: Women with diagnosis stage I to III ILC or (IDC) between 2010 2018 were identified National Cancer Database. Baseline characteristics compared IDC using Chi-square test categorical variables Mann-Whitney U continuous variables. Five-year overall...